Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY

E Leistad1, G Aksnes, E Verburg

  • 1Institute for Experimental Medical Research, University of Oslo, Ullevål Hospital, Norway. elizabeth.leistad@ioks.uio.no

Circulation
|May 1, 1996
PubMed

Insights

Calcium channel blocker verapamil reduced atrial contractile dysfunction after atrial fibrillation, suggesting calcium influx contributes to this condition. The calcium agonist BAY K8644 worsened dysfunction.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Pharmacology

Background:

  • Atrial contractility is reduced after atrial fibrillation cessation.
  • The mechanism of this post-fibrillation atrial dysfunction is unknown.
  • Intracellular calcium overload from rapid depolarization is a hypothesized cause.

Purpose of the Study:

  • To investigate the role of transsarcolemmal calcium influx in post-fibrillation atrial dysfunction.
  • To examine the effects of calcium channel blockers and agonists on this dysfunction.
  • To determine if atrial ischemia contributes to the observed dysfunction.

Main Methods:

  • Open-chest pigs with induced atrial fibrillation were studied.
  • Atrial contractility was measured by left atrial diameter shortening.
  • Verapamil (calcium antagonist) or BAY K8644 (calcium agonist) was administered before the second fibrillation period.

Main Results:

  • Verapamil reduced the degree and duration of post-fibrillation atrial contractile dysfunction.
  • BAY K8644 increased post-fibrillation atrial contractile dysfunction.
  • Atrial tissue levels of creatine phosphate decreased slightly; ATP and lactate remained unchanged, indicating no significant ischemia.

Conclusions:

  • Transsarcolemmal calcium influx contributes to atrial contractile dysfunction following atrial fibrillation.
  • Calcium channel antagonism (verapamil) ameliorates this dysfunction.
  • Calcium channel agonism (BAY K8644) exacerbates post-fibrillation atrial contractile dysfunction.
Abstract

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...